Trial · NCT01485536
A Study of the HSP90 Inhibitor AUY922
NCT01485536, Phase 2, Terminated, M.D. Anderson Cancer Center; results first posted 2017-01-23
3 sourcestrials-2026-11-12-0.4.0
Cite this record
ConductScience Library. A Study of the HSP90 Inhibitor AUY922. Trials, record NCT01485536. Release trials-2026-11-12-0.4.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT01485536
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- A Study of the HSP90 Inhibitor AUY922
- NCT number
- NCT01485536
- Status
- Terminated
- Phases
- Phase 2
- Enrollment
- 21 participants, actual
- Lead sponsor
- M.D. Anderson Cancer Center
- Conditions
- Lymphoma
- Interventions
- AUY922
- First posted
- 2011-12-05
- Last updated
- 2017-01-23
- Results first posted
- 2017-01-23
- Limitations and caveats
- Although the study surpassed the first futility endpoint for DLBCL cohort, it was terminated early due to limited responses and significant toxicities witnessed in the entire cohort of the study.
Source ClinicalTrials.gov
Registered outcomes2
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Objective Response in Participants With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL) and Peripheral T-cell Lymphoma (PTCL) | 56 days | Objective Response defined as Complete (CR) and Partial (PR) Response. Computed tomography (CT) and Positron emission tomography (PET) scans done after every 2 cycles to assess efficacy using Cheson Criteria (2007) which lists CR as disappearance of all evidence of disease, and PR as regression of measurable disease and no new sites. |
| Primary | Overall Response Rate (ORR) | Up to 12 cycles or 48 weeks | Percentage of participants with objective response defined as Complete (CR) and Partial (PR) Response. Computed tomography (CT) and Positron emission tomography (PET) scans done after every 2 cycles to assess efficacy using Cheson Criteria (2007) which lists CR as disappearance of all evidence of disease, and PR as regression of measurable disease and no new sites. |
Source ClinicalTrials.gov
Outcomes2
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Objective Response in Participants With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL) and Peripheral T-cell Lymphoma (PTCL) | 56 days | One participant withdrew therefore was not evaluable for the outcome and is excluded from analysis | Participants | COUNT_OF_PARTICIPANTS |
| PRIMARY | Overall Response Rate (ORR) | Up to 12 cycles or 48 weeks | One participant withdrew therefore was not evaluable for the outcome and is excluded from analysis | percentage of participants | NUMBER |
Source ClinicalTrials.gov
Results by group4
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Objective Response in Participants With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL) and Peripheral T-cell Lymphoma (PTCL) | AUY922 | DLBCL (N=14) | 1 | Participants | |
| Objective Response in Participants With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL) and Peripheral T-cell Lymphoma (PTCL) | AUY922 | PTCL (N=6) | 1 | Participants | |
| Overall Response Rate (ORR) | AUY922 | DLBCL (N=14) | 7 | percentage of participants | |
| Overall Response Rate (ORR) | AUY922 | PTCL (N=6) | 17 | percentage of participants |
Source ClinicalTrials.gov
Participant flow3
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | AUY922 | 21 | |
| Overall Study | COMPLETED | AUY922 | 17 | |
| Overall Study | NOT COMPLETED | AUY922 | 4 |
Source ClinicalTrials.gov
Adverse events113
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Abdominal pain | Gastrointestinal disorders | AUY922 | 5 | 20 | 6 |
| other | Activated partial thromboplastin time prolonged | Investigations | AUY922 | 1 | 20 | 1 |
| other | Alanine aminotransferase increased | Investigations | AUY922 | 1 | 20 | 1 |
| other | Alkaline phosphatase increased | Investigations | AUY922 | 1 | 20 | 1 |
| other | Allergic reaction | Immune system disorders | AUY922 | 1 | 20 | 1 |
| other | Allergic rhinitis | Respiratory, thoracic and mediastinal disorders | AUY922 | 2 | 20 | 2 |
| other | Anemia | Blood and lymphatic system disorders | AUY922 | 9 | 20 | 16 |
| other | Anorexia | Metabolism and nutrition disorders | AUY922 | 2 | 20 | 3 |
| other | Anxiety | Psychiatric disorders | AUY922 | 3 | 20 | 3 |
| other | Aspartate aminotransferase increased | Investigations | AUY922 | 1 | 20 | 1 |
1 to 10 of 113Source ClinicalTrials.gov
See all 113 adverse eventsAdverse event totals3
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | AUY922 | ||
| Total, other adverse events | AUY922 | 20 | 20 |
| Total, serious adverse events | AUY922 | 4 | 20 |
Source ClinicalTrials.gov
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Source
- Release
- trials-2026-11-12-0.4.0
- Release manifest SHA-256
- 0f4a8d8c48aee2a7573ae0fa94ecbeab70c1adbe449bbc95c424bc7d3e97b9d4
- Registry capture
- 2026-11-12
- Results copy, AACT
- 2026-03-23
- NIH clinical studies file
- 2026-11-13
Source ClinicalTrials.gov
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNone stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT01485536
GET https://conductscience.org/api/trials/v1/NCT01485536/events?page=2